What smart money is saying about Madrigal Pharmaceuticals
2 funds in our archive have pitched Madrigal Pharmaceuticals, most recently Artisan US Small Cap Growth Strategy in September 2025.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Get an email when a fund buys, sells or pitches it
Position history
Between Q2 2025 and Q3 2026, 2 fund letters reported a position in Madrigal Pharmaceuticals, with 1 buy (opened or added) and 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 1 | 0 |
| Q3 2025 | 1 | 1 | 0 | 1 |
| Q2 2025 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 2 positions · 2 moves
- TrimmedBaron Health Care FundSeptember 2026
“Top net sales for the quarter Net Amount Sold ($M) AstraZeneca PLC 2.4 Madrigal Pharmaceuticals, Inc. 2.3 Gilead Sciences, Inc. 2.3 BillionToOne, Inc. 2.3 RadNet, Inc. 1.5 We sold AstraZeneca PLC for the reasons discussed earlier. We sold Madrigal Pharmaceuticals, Inc. to manage risk ahead of a competitor’s clinical trial readout.”
Madrigal Pharmaceuticals - September 2025
“Madrigal Pharmaceuticals is a commercial-stage biotech company focused on treating metabolic dysfunction-associated steatohepatitis (MASH)—a serious liver disease with significant unmet need— through its lead drug, Rezdiffra™. As the first and only FDA-approved treatment for MASH with moderate to advanced fibrosis (F2–F3), Rezdiffra offers clinically meaningful efficacy and a favorable safety profile. During the quarter, we increased our position in Madrigal Pharmaceuticals to a small CropSM, driven by the successful launch of its F2–F3 therapy and effective execution in pricing negotiations with insurers.”
Madrigal Pharmaceuticals
Fund coverage · 2 theses
- Artisan US Small Cap Growth StrategySeptember 2025
Madrigal Pharmaceuticals is a biotech company focused on treating metabolic dysfunction-associated steatohepatitis (MASH) with its FDA-approved drug Resdiffra™.
Read the full thesis - Artisan US Small Cap Growth StrategyJune 2025
Madrigal Pharmaceuticals is a leading biotechnology company specializing in the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with its FDA-approved drug Resdifra™, which effectively targets liver fibrosis.
Read the full thesis
Read every full thesis on Madrigal Pharmaceuticals
Read all 2 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→